| 5.7 0.2 (3.65%) | 07-02 11:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.19 |
1-year : | 7.67 |
| Resists | First : | 6.16 |
Second : | 6.57 |
| Pivot price | 5.97 |
|||
| Supports | First : | 5.5 |
Second : | 4.57 |
| MAs | MA(5) : | 5.94 |
MA(20) : | 5.98 |
| MA(100) : | 5.04 |
MA(250) : | 6.23 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 18.3 |
D(3) : | 29.6 |
| RSI | RSI(14): 39 |
|||
| 52-week | High : | 13.59 | Low : | 2.84 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRE ] has closed below the lower bollinger band by 34.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ PRE ] is to continue within current trading range. It is unclear right now based on current values. 54.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.01 - 6.04 | 6.04 - 6.07 |
| Low: | 5.75 - 5.79 | 5.79 - 5.83 |
| Close: | 5.86 - 5.92 | 5.92 - 5.97 |
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Mon, 01 Jul 2024
Prenetics boosts board with new independent directors By Investing.com - Investing.com
Mon, 01 Jul 2024
Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors - The Bakersfield Californian
Mon, 01 Jul 2024
Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors - StockTitan
Mon, 01 Jul 2024
Prenetics Global Limited (PRE) Stock Moves -1.14%: What You Should Know - Yahoo Movies Canada
Sat, 29 Jun 2024
Prenetics Global Limited (NASDAQ:PRE) Short Interest Update - MarketBeat
Thu, 27 Jun 2024
Investors Aren't Entirely Convinced By Prenetics Global Limited's (NASDAQ:PRE) Revenues - Yahoo Canada Shine On
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 11 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 21.3 (%) |
| Held by Institutions | 27.2 (%) |
| Shares Short | 34 (K) |
| Shares Short P.Month | 80 (K) |
| EPS | -4.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.32 |
| Profit Margin | -262.2 % |
| Operating Margin | -142.9 % |
| Return on Assets (ttm) | -10.9 % |
| Return on Equity (ttm) | -23.8 % |
| Qtrly Rev. Growth | -63.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.18 |
| EBITDA (p.s.) | -3.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.29 |
| PEG Ratio | 0 |
| Price to Book value | 0.33 |
| Price to Sales | 2.51 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|